Current biomarkers in immunotherapy
Immunotherapy approaches have revolutionized medical oncology in the last years. However, still only a fraction of patients is responding. Given the risk of side effects without efficacy, therefore, b
Related Articles
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer
The infiltration of tumor-infiltrating B cells and plasma cells in early-stage breast cancer has been associated with a reduced risk of distant metastasis. However, the…
Genomic and Clinical Landscape of Metastatic HR+ Breast Cancers With ESR1 Alterations
Read it now on PracticeUpdate.com
Genomic and Clinical Landscape of Metastatic HR+ Breast Cancers With ESR1 Alterations
Read it now on PracticeUpdate.com
Safety of solid oncology drugs in older patients: a narrative review
The older population represents ∼50%-60% of the population of newly diagnosed patients with cancer. Due to physiological and pathological aging and the increased presence of…
Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?
The management of hormone receptor-positive (HR+) early breast cancers (EBC) is based on a risk-adapted optimization strategy escalating adjuvant endocrine treatment (ET) with the addition…
Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology
In the era of precision oncology, the management of triple-negative breast cancer (TNBC) is rapidly changing and becoming more complicated with a variety of chemotherapy,…
Detection of antibody–drug conjugate-induced interstitial lung disease using circulating cell-free DNA
The increasing use and anticipated future adoption of antibody–drug conjugates (ADCs) present a significant challenge in identifying and monitoring patients for the development of potentially…
Targeting HER2-low gastric cancer, summary by Erman Akkus – OncoDaily
Targeting HER2-low gastric cancer, summary by Erman Akkus / A Ooki, Ankara University Faculty of Medicine, Breast Cancer, cancer, Erman Akkus, ESMO Open,
HER2-low gastric cancer: is the subgroup targetable?
Therapeutic developments in the targeting of human epidermal growth factor receptor 2 (HER2)-expressing gastric cancer have followed the dramatic success of HER2-expressing breast cancer treatment,…
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study
Interstitial lung disease (ILD) encompasses a heterogeneous group of disorders sharing pathophysiological inflammatory mechanisms, leading to parenchymal distortions. The prevalence of ILD with new cancer…